A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio CareDx, Inc. (Nasdaq: CDNA) — The ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

A total of 641 eligible cases were enrolled from June 2022 to October 2023 from seven hospitals in China. The sensitivity rates for all syndromes ranged from 70.37% to 92.00%, with the highest rate ...

Hospitals are facing a steady rise in payment disputes over their assignment of a Diagnosis Related Group (DRG). These disputes fall into two general categories: coding-based DRG downgrades and ...

By utilizing a standardized methodology for evaluating novel digital measures, sDHT developers, biostatisticians and clinical researchers will be able to navigate the complex validation landscape more ...

NEW YORK – Personalized cancer firm Artera this week presented four studies on its multimodal artificial intelligence (MMAI) digital pathology-based risk stratification platform at the annual ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

NEW YORK – Spanish diagnostic firm MiMark Diagnostics is progressing toward clinical validation and commercialization of its minimally invasive test for endometrial cancer. The spinout of Vall ...